Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Frechen – page 28

1 443 clinical trials in Frechen, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Frechen at a glance
1 443
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 443 trials in Frechen

Open in trial search

Study on Ivosidenib, Azacitidine, and Venetoclax for Adults with Newly Diagnosed IDH1-Mutated Acute Myeloid Leukemia Ineligible for Intensive Chemotherapy

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Study on the Effectiveness of Lisaftoclax and Azacitidine in Adults with Newly Diagnosed Higher Risk Myelodysplastic Syndrome

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:Ascentage Pharma Group Inc.

Study on the Effects of TRI-001 for Patients with Chronic Limb Threatening Ischemia Due to Peripheral Arterial Disease

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Allogeneic regulatory macrophages
  • Sponsor:Ferring Ventures GmbH

Breast cancer

Recruiting

Study of inavolisib, palbociclib and letrozole combination for patients with advanced hormone receptor-positive, HER2-negative breast cancer with PIK3CA mutation

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Inavolisib
  • Sponsor:F. Hoffmann-La Roche AG

Study of Ifinatamab Deruxtecan and Pembrolizumab, With or Without Chemotherapy, for Patients With Untreated Advanced Esophageal Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:Merck Sharp & Dohme LLC

Study of ABBV-400 and Budigalimab for Adults with Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Budigalimab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Study on the Safety and Effects of NSC001 and Trospium Chloride for Patients with Mild to Moderate Alzheimer's Disease

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:NGX-267
  • Sponsor:Nsc Therapeutics GmbH

Study on the Effectiveness and Safety of GAL-101 Eye Drops for Patients with Geographic Atrophy from Age-Related Macular Degeneration

Investigational
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Na-GAL-IPA
  • Sponsor:Galimedix Therapeutics Inc.

Anaemia+1

Recruiting

Study of Elritercept for Treating Anemia in Adults with Low to Intermediate Risk Myelodysplastic Syndromes

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Elritercept
  • Sponsor:Takeda Development Center Americas Inc.

Study on Osimertinib and Chemotherapy for Stage IV Non-Small Cell Lung Cancer with Atypical EGFR Mutations

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Heidelberg University

Study on Venetoclax, Obinutuzumab, and Pirtobrutinib for Patients with Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Obinutuzumab
  • Sponsor:University Of Cologne

Study of N-Acetyl-L-Leucine in Patients with Ataxia-Telangiectasia: A Phase III Trial

Investigational
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:L-Acetylleucine
  • Sponsor:Intrabio Limited

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Frechen

What the registry says about research in the country

01 Hematologic Oncology

Clinical research focusing on chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), evaluating new combination therapies with venetoclax and comparing different treatment durations based on measurable residual disease.

  • Treatment Duration Optimization
  • Combination Therapy Assessment
  • Disease Progression Monitoring

Innovative approaches in blood cancer treatment aimed at improving patient outcomes through personalized therapy duration.

02 Supportive Cancer Care

Investigation into preventing and managing chemotherapy-induced polyneuropathy (CIPN) using Aconite Pain Oil, with a focus on improving quality of life for cancer patients undergoing chemotherapy treatment.

  • Neuropathy Prevention
  • Symptom Management
  • Quality of Life Enhancement

Novel approaches to reducing chemotherapy side effects and maintaining treatment effectiveness.

03 Precision Medicine

Advanced research incorporating artificial intelligence to evaluate treatment resistance in patients with polycythemia vera, focusing on predicting hydroxyurea resistance patterns.

  • AI-Based Prediction Models
  • Treatment Resistance Analysis
  • Personalized Treatment Strategies

Integration of machine learning with clinical practice to optimize treatment selection and patient outcomes.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.